Literature DB >> 8733948

A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples.

K E Fattinger1, D Verotta.   

Abstract

In a pharmacokinetics context deconvolution facilitates the following: (i) Given data obtained after intravascular (generally intravenous) input one may estimate the disposition function; (ii) given the disposition function and data obtained after extravascular administration one may estimate the extravascular to vascular input rate function. In general if the data can be represented by the convolution of two functions, of which one is unknown, deconvolution allows the estimation of the unknown one. Attention has been given in the past to deconvolution and in particular to its nonparametric variants. However, in a population context (multiple observations collected in each of a group of subjects) the use of nonparametric deconvolution is limited to either analyzing each subject separately or to analyzing the aggregate response from the population without specifying subject-specific characteristics. To our knowledge a fully nonparametric deconvolution method in which subject specificity is explicitly taken into account has not been reported. To do so we use so-called "longitudinal splines." A longitudinal spline is a nonparametric function composed of a template spline, in common to all subjects, and of a distortion spline representing the difference of the subject's function from the template. Using longitudinal splines for input rate or disposition function one obtains a solution to the problem of taking subject specificity into account in a nonparametric deconvolution context. To obtain estimates of longitudinal splines we consider three different methods: (1) parametric nonlinear mixed effect, (2) least squares, and (3) two-stage. Results obtained in one simulated and two real data analyses are shown.

Mesh:

Year:  1995        PMID: 8733948     DOI: 10.1007/bf02353463

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  19 in total

1.  A nonparametric subject-specific population method for deconvolution: II. External validation.

Authors:  K E Fattinger; D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

Review 2.  An inequality-constrained least-squares deconvolution method.

Authors:  D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1989-04

3.  Models for longitudinal data: a generalized estimating equation approach.

Authors:  S L Zeger; K Y Liang; P S Albert
Journal:  Biometrics       Date:  1988-12       Impact factor: 2.571

4.  A model-free approach to estimation of relative potency in dose-response curve analysis.

Authors:  V Guardabasso; D Rodbard; P J Munson
Journal:  Am J Physiol       Date:  1987-03

5.  Reconstructing the rate of appearance of subcutaneous insulin by deconvolution.

Authors:  C Cobelli; A Mari; S Del Prato; S De Kreutzenberg; R Nosadini; I Jensen
Journal:  Am J Physiol       Date:  1987-11

6.  Estimating bioavailability when clearance varies with time.

Authors:  M O Karlsson; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-06       Impact factor: 6.875

7.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

8.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

9.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

10.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Authors:  L B Sheiner
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

View more
  12 in total

1.  Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile.

Authors:  K Park; D Verotta; S K Gupta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

2.  Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.

Authors:  Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

Review 3.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.

Authors:  Chantal Csajka; David Drover; Davide Verotta
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

5.  Application of SPLINDID, a semiparametric, model-based method for pharmacogenomic modeling of mRNA dynamics.

Authors:  Kavitha Bhasi; Alan Forrest; Murali Ramanathan
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

6.  Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.

Authors:  D R H Huntjens; A Strougo; A Chain; A Metcalf; S Summerfield; D J M Spalding; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

7.  A nonparametric subject-specific population method for deconvolution: II. External validation.

Authors:  K E Fattinger; D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

8.  A semiparametric method for describing noisy population pharmacokinetic data.

Authors:  K Park; D Verotta; T F Blaschke; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1997-10

9.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

10.  Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.

Authors:  Josef A Vogt; Christian Denzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.